The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Use of serological surveys to generate key insights into the changing global landscape of infectious disease
Open accessAbstract
A central conundrum in the study of infectious disease dynamics is to defi ne the landscape of population immunity. The proportion of individuals protected against a specifi c pathogen determines the timing and scale of outbreaks, and the pace of evolution for infections that can evade prevailing humoral immunity. Serological surveys provide the most direct measurement to defi ne the immunity landscape for many infectious diseases, yet this methodology remains underexploited. To address this gap, we propose a World Serology Bank and associated major methodological developments in serological testing, study design, and quantitative analysis, which could drive a step change in our understanding and optimum control of infectious diseases. Epidemic dynamics result from an interaction between the contagious spread of infection, the resulting depletion of population susceptibility, and its replenishment via births, immigration, or waning immunity. Understanding this interaction is key to assess the eff ect of vaccination, which artifi cially reduces the number of people susceptible to infection. Researchers mainly observe infection dynamics and the eff ect of population (or herd) immunity in limiting spread via surveillance of clinically apparent cases of infection or deaths. This method has led to some powerful insights; however, even in the simplest instances in which subclinical infection is uncommon, cases only provide information about the dynamics of infection. Susceptibility and immunity are hidden variables. For infections that people can be completely immunised against, such as measles, susceptible reconstruction can be used to estimate immune profi les, but infection prevalence and vaccination coverage records are frequently inadequate to capture key social and geographical heterogeneities. Additionally, inference is weakened if the risk of infection is low. Serological surveys (usually used to quantify the proportion of people positive for a specifi c antibody or, better yet, the titre or concentrations of an antibody) are potentially the most direct and informative technique available to infer the dynamics of a population’s susceptibility and level of immunity. However, the use of current serological tests varies greatly depending on type of pathogens and there are major methodological gaps in some areas for some pathogens and tests. In terms of use of current serological methods, infections can be classifi ed into four broad groups (appendix). The fi rst group contains acute immunising, antigenically stable pathogens (eg, measles, rubella, and smallpox) for which serology provides a strong signal of lifetime protection and a clear marker of past infection (or vaccination). The second group contains immunising, but antigenically variable pathogens (eg, infl uenza, invasive bacterial diseases, and dengue). Despite complexities (appendix), serology in some cases can provide powerful evidence, both for vaccine formulation and pandemic planning. A serum bank would have been extremely useful in interpretation of the unusual profi le of susceptibility associated with age in the 2009 infl uenza pandemic. For these fi rst two groups, if suitable serum banks existed, the deployment of current serological tests could have helped to clarify the association between serological profi les and protective immunity. The third group includes infections for which infectioninduced antibodies are not thought to be protective, such as tuberculosis in which the targets of the immune response vary with stage of infection; malaria, whereby infected erythrocytes generate several antibodies whose individual importance has not been fully elucidated (and might indicate exposure rather than protection); and HIV. Although antibodies might not be representative of immunity against a pathogen, they do show current or previous infection. Finally, the last broad grouping consists of infections that do not lead to reliably sustained, measurable antibody responses or for which presence of specifi c antibodies do not correlate with protection from future infection. These include many enteric infections and the human papillomavirus. In these cases, serological data can nonetheless be valuable to assess a population’s coverage of vaccine programmes if vaccination leads to long-lasting antibody responses. In the context of public health, for immunisation against group one infections, vaccination programmes aim to protect vaccinated individuals and indirectly protect unvaccinated individuals by maintaining high population immunity. If a valid correlate of immunity is measurable in sera, serological surveys could be used to identify population subgroups in which immunity is low, or even to identify individuals in whom immunity has waned, and directly inform targeted vaccination strategies (appendix). Household surveys are a major source of data for vaccination coverage in low-income countries. The recent extension of eff orts to measure biomarkers for infections such as HIV (eg, the Demographic Health Surveys) could provide infrastructure for sera collection for an expanded range of infections, thus leveraging an existing platform. For many infections, however, to Lancet 2016; 388: 728–30
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herd Immunity: History, Theory, Practice
Fine, P. E. M. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036121 · Cited by 905
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi206 · Cited by 743
Measles Antibody: Reevaluation of Protective Titers
Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R., & Orenstein, W. A. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.5.1036 · Cited by 608
Bjørnstad, O. N., Finkenstädt, B. F., & Grenfell, B. T. (2002) · Ecological Monographs · doi:10.1890/0012-9615(2002)072[0169:domees]2.0.co;2 · Cited by 547
Self-citationDrakeley, C. J., Corran, P. H., Coleman, P. G., Tongren, J. E., McDonald, S. L. R., Carneiro, I., Malima, R., Lusingu, J., Manjurano, A., Nkya, W. M. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408725102 · Cited by 510
Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China
Lessler, J., Riley, S., Read, J. M., Wang, S., Zhu, H., Smith, G. J. D., Guan, Y., Jiang, C. Q., & Cummings, D. A. T. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002802 · Cited by 243
Self-citationTee, K. K., Lam, T. T.-Y., Chan, Y. F., Bible, J. M., Kamarulzaman, A., Tong, C. Y. W., Takebe, Y., & Pybus, O. G. (2010) · Journal of Virology · doi:10.1128/jvi.01019-09 · Cited by 226
Cutts, F. T., Izurieta, H. S., & Rhoda, D. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001404 · Cited by 179
Self-citationBjørnstad, O. N., Finkenstadt, B. F., & Grenfell, B. T. (2002) · Ecological Monographs · doi:10.2307/3100023 · Cited by 112
Self-citationKerkhove, M. D. V., & Ferguson, N. M. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.097949 · Cited by 85
Self-citation
Cited by
Infectious disease in an era of global change
Baker, R. E., Mahmud, A. S., Miller, I. F., Rajeev, M., Rasambainarivo, F., Rice, B. L., Takahashi, S., Tatem, A. J., Wagner, C. E., Wang, L.-F., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00639-z · Cited by 2,059
Self-citationPollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Moss, W. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31463-0 · Cited by 530
Safiabadi Tali, S. H., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi-Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 405
Urbanization and humidity shape the intensity of influenza epidemics in U.S. cities
Dalziel, B. D., Kissler, S., Gog, J. R., Viboud, C., Bjørnstad, O. N., Metcalf, C. J. E., & Grenfell, B. T. (2018) · Science · doi:10.1126/science.aat6030 · Cited by 397
Self-citation
Metadata
- Authors
- Metcalf, C. J. E., Farrar, J., Cutts, F. T., Basta, N. E., Graham, A. L., Lessler, J., Ferguson, N. M., Burke, D. S., & Grenfell, B. T.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 388
- Issue
- 10045
- Pages
- 728-730
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2331125559
- Cited by
- 286
- References
- 11
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of serological surveys to generate key insights into the changing global landscape of infectious disease. https://app.cochat.ai/papers/10.1016/s0140-6736(16)30164-7
- The paper
- Metcalf, C. J. E., Farrar, J., Cutts, F. T., Basta, N. E., Graham, A. L., Lessler, J., Ferguson, N. M., Burke, D. S., & Grenfell, B. T. (2016). Use of serological surveys to generate key insights into the changing global landscape of infectious disease. The Lancet. https://doi.org/10.1016/s0140-6736(16)30164-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.